AMBER GOLEMBESKI RN
Prescription History 1669928495
Nurse Practitioner in Sheboygan, WI

NPI Status: Active since August 31, 2016

Contact Information

924 N TAYLOR DR
SHEBOYGAN, WI
ZIP 53081
Phone: (920) 395-7210
Fax: (920) 395-7211

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for AMBER GOLEMBESKI RN, an active Nurse Practitioner specialist practicing in Sheboygan, WI. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 195 documented patient claims. Among these therapy options, the most frequently utilized medication is Paxlovid (Eua), which accounts for 75 claims alone.


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 387
WI State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills68.1
Peer Average Days Supply1,588
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.9% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $384.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.01

State Avg Cost Per Claim

$51.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 191
WI State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.0
Peer Average Days Supply195
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $237.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.88

State Avg Cost Per Claim

$14.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 96
WI State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply407
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $175.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.97

State Avg Cost Per Claim

$25.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 21.5
Days Supply 610
WI State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills84.1
Peer Average Days Supply2,506
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.8% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $151.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.92

State Avg Cost Per Claim

$18.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Lagevrio (Eua)

Generic Formulation: MolnupiravirSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 195
WI State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply151
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.0% more claims than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,399.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.88

State Avg Cost Per Claim

$10.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Molnupiravir is a product that the FDA is allowing to be given for emergency use to treat COVID-19. It is used by adults 18 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with molnupiravir. Molnupiravir works by preventing the growth of the virus that causes COVID-19. More information about molnupiravir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use. There is limited information about how safe and effective molnupiravir is for treating COVID-19. Study results show that molnupiravir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of molnupiravir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Paxlovid (Eua)

Generic Formulation: Nirmatrelvir/RitonavirSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 75
30-Day Fills 75.0
Days Supply 374
WI State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.2
Peer Average Days Supply116
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 226.1% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $787.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.51

State Avg Cost Per Claim

$10.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Prednisone

Generic Formulation: PrednisoneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 88
WI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills53.7
Peer Average Days Supply1,056
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.5% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $29.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.76

State Avg Cost Per Claim

$7.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like AMBER GOLEMBESKI RN provides transparency into local medical care patterns within Sheboygan, WI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.